- £4.24bn
- £5.02bn
- $2.88bn
- 74
- 50
- 75
- 77
REG - Hikma Pharmaceutical - Hikma completes FDA response for generic Advair®
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Block Listing Application
AnnouncementREG - Hikma Pharmaceutical - Trading Statement
AnnouncementREG - Hikma Pharmaceutical - Total Voting Rights
AnnouncementREG - Hikma Pharmaceutical - Holding(s) in Company
AnnouncementREG - Hikma Pharmaceutical - Block listing Interim Review
AnnouncementREG - Hikma Pharmaceutical - Total Voting Rights
AnnouncementRCS - Hikma Pharmaceutical - Hikma launches prefilled syringes in the US
AnnouncementREG - Hikma Pharmaceutical - Notice of Accession of Guarantor
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Total Voting Rights
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementRCS - Hikma Pharmaceutical - Hikma expands nasal spray capabilities
AnnouncementREG - Hikma Pharmaceutical - Half-year Report
AnnouncementREG - Hikma Pharmaceutical - Total Voting Rights
AnnouncementRCS - Hikma Pharmaceutical - Hikma and Richter sign agreement for cariprazine
AnnouncementRCS - Hikma Pharmaceutical - Hikma and Civica Rx sign long-term agreement
AnnouncementREG - Hikma Pharmaceutical - Notice of Results
Announcement